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Abstract
Rationale The preclinical characterization of a series of
aryloxypyridine amides has identified JNJ-39220675 ((4-
cyclobutyl-1,4-diazepan-1-yl)(6-(4-fluorophenoxy)pyridin-
3-yl)methanone) as a high-affinity histamine H3 receptor
antagonist and a candidate for further drug development
particularly in the treatment of alcohol-related behaviors.
Objective This study measured brain histamine H3 receptor
blockade by JNJ-39220675 (1 mg/kg) in the female baboon.
Methods Positron emission tomography imaging and [11C]
GSK189254, a reversible high-affinity radiotracer with
specificity for the histamine H3 receptor, was used to mea-
sure histamine H3 receptor availability at baseline and after
i.v. and oral administration of JNJ-39220675 (1 mg/kg) in
the anesthetized baboon. Histamine H3 receptor availability
was estimated as the total distribution volume (VT) in brain
regions. The sensitivity of [11C]GSK189254 binding to
injected mass and carryover effects was determined.
Results JNJ-39220675 produces robust (ca. 90 %) blockade
of [11C]GSK189254 binding after i.v. and oral administra-
tion. After oral administration of JNJ-39220675 (1 mg/kg),
the fractional receptor occupancy was >0.9 at 90 min with a
slight increase from 90 to 240 min. Similar to prior studies
in humans, VT was highly sensitive to the mass of
GSK189254 with ED50 estimated to be 0.16 μg/kg.
Conclusions The robust blockade of binding of [11C]
GSK189254 by JNJ-39220675 demonstrates that this com-
pound readily penetrates the blood–brain barrier and occu-
pies the histamine H3 receptor after oral administration at
low plasma concentrations (∼1 ng/cc) supporting further
drug development for alcohol addiction and other disorders.
This study corroborates prior reports of the high sensitivity
of [11C]GSK189254 to injected mass at doses >0.1 μg/kg.
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Introduction
Histamine is synthesized in histaminergic neurons which are
localized in the tuberomamillary nucleus in the posterior
hypothalamus and project widely throughout the central
nervous system (Brown et al. 2001). The histamine H3
receptor is one of four histamine receptor subtypes (Hill et
al. 1997). It is predominantly expressed in the brain, with
the highest density in the basal ganglia as well as hippo-
campus and cortical areas (Martinez-Mir et al. 1990). His-
tamine H3 receptors have been identified as presynaptic
autoreceptors on histamine neurons where they negatively
regulate histamine release, thereby modulating histaminer-
gic tone (Hill et al. 1997; Arrang et al. 1983). The H3
receptor is also a presynaptic heteroreceptor in nonhistamine-
containing neurons in both the central and peripheral nervous
systems. Nonhistamine-containing neurons modulated by the
H3 receptor utilize a variety of neurotransmitters including
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gamma-aminobutyric acid, noradrenaline, acetylcholine, dopa-
mine, and serotonin.
Histamine H3 receptors are involved in a variety of
physiological functions including sleep/waking (arous-
al), motor activity, eating behavior, and cognitive func-
tion (Passani et al. 2004, 2011; Esbenshade et al.
2008). There is also evidence that antagonism of his-
tamine H3 receptors will selectively produce enhanced
neurotransmission in a variety of these neuronal sys-
tems and that the increase in transmitter turnover will
have beneficial consequences for cognition, arousal,
and a variety of other CNS processes (Witkin and
Nelson 2004) as well as obesity and diabetes mellitus
(Yoshimoto et al. 2006). Of particular interest is the
potential for H3 antagonists in the treatment of alco-
holism which is a major health problem worldwide
with overall economic costs approaching $200 billion
annually in USA alone. Three drugs in USA, disulfi-
ram, naltrexaone, and acomposate, are approved for the
treatment of alcoholism, but none of these are truly
effective and all demonstrate high relapse rates. The
cortico-mesolimbic area of the brain where alcohol and
other drugs of abuse exert their reinforcing and reward-
ing effect is rich in histamine H3 receptors, and evi-
dence suggests that the histaminergic system is
involved in alcohol-induced behaviors via interactions
with this system. Preclinical studies in rodents found
high alcohol preference and low alcohol sensitivity
correlated with brain histamine and H3-mediated pro-
cesses (Panula and Nuutinen 2011). Thus the investi-
gation of the neurobiology of the brain histamine H3
receptors as well as the therapeutic potential of drugs
which target this relatively new molecular target has
received considerable attention (Bonaventure et al.
2007) as has the development of methods for assessing
their in vivo behavior in the setting of drug R&D.
Letavic et al. (2010) recently reported the results of a
preclinical characterization of a large series of aryloxypyr-
idine amides and identified one of these ((4-cyclobutyl-1,4-
diazepan-1-yl)(6-(4-fluorophenoxy)pyridin-3-yl)metha-
none, JNJ-39220675; Fig. 1a) as a high-affinity histamine
H3 receptor antagonist (Ki, 1.4 nM). In addition to its clean
receptor-binding profile, functional assays revealed that
JNJ-39220675 significantly increased histamine levels in
the frontal cortex consistent with histamine H3 receptor
antagonism while also significantly increasing wake dura-
tion following s.c. administration in rats (Letavic et al.
2010). Support for the H3 alcohol link also comes from a
recent report that JNJ-39220675 dose-dependently reduced
both alcohol intake and preference in alcohol-preferring rats
without changing alcohol pharmacokinetics (Galici et al.
2011). These studies support the further development of
JNJ-39220675 as drug candidate and the current study to
further characterize the behavior of a single dose of JNJ-
39220675 with respect to in vivo BBB penetration and
histamine H3 receptor occupancy in nonhuman primates.
[11C]GSK189254 (6-[(3-cyclobutyl-2,3,4,5-tetrahydro-
1H-3-benzazepin-7-yl)oxy]-N-[11C]methyl-3-pyridinecar-
boxamide hydrochloride; Fig. 1b) is a high-affinity, revers-
ibly binding radioligand which has been recently
synthesized and validated as a radiotracer with specificity
for the histamine H3 receptor both in pigs (Plisson et al.
2009) and in humans (Ashworth et al. 2010). Moreover, it is
labeled with carbon-11 which has a 20.4-min half-life mak-
ing it ideal for serial studies in which an individual animal or
human subject can serve as a control for a subsequent drug
treatment scan. However, the previous study of [11C]
GSK189254 in humans has cautioned that its binding is
highly sensitive to the levels of carrier GSK189254 present
and that measures of histamine H3 receptor availability
requires high-specific activity of the radiotracer in order to
avoid receptor inhibition by the mass of the “tracer” itself
(Ashworth et al. 2010). Here, we used the serial study
design in the anesthetized female baboon to determine
whether JNJ-39220675 administration inhibits [11C]
GSK189254 binding in the brain. We also examined the
effect of specific activity of [11C]GSK189254 on baseline
measures of histamine H3 receptor availability in order to
account for tracer mass and carryover effects.
Materials and methods
Study design
Six female baboons received 14 baseline scans with [11C]
GSK189254. In one baboon (Reilly), the baseline was re-
peated on the same day. In a second (Lulu), the baseline
scan was repeated on two different days 1 month apart; in a
third (Kennedy), baseline scans were done 2.2 years apart.
In three animals (Daisy, Friendly, and Kennedy), the base-
line scan was followed by an intravenous dose of JNJ-
39220675 administered 10 min prior to a second [11C]
GSK189254 scan. In two animals (Spicey and Daisy), after
a baseline scan, JNJ-39220675 (1 mg/kg) was administered
via a nasogastric tube followed by the second and third
scans at 90 and 240 min after the drug. For one of the
studies in which JNJ-39220675 was administered orally,
plasma samples were collected at baseline (to serve as a
blank), at the time of the second PET scan, and at the end ofFig. 1 Structures of JNJ-39220675 and [11C]GSK189254
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the second scan 90 min later. The samples were centrifuged,
frozen, and stored at −20 °C until analysis of drug levels.
Drug administration
JNJ-39220675 (1 mg/kg) was dissolved in 5 % dextrose
(1.2 mL 5 % dextrose/mg of JNJ-39220675) with warming
and filtered through a 0.22-μ filter for intravenous adminis-
tration. The solution was prepared in the same way for
administration through the nasogastric tube but not filtered.
[11C]GSK189254 preparation
[11C]GSK189254 was prepared by the alkylation of 6-[(3-
cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy-
pyridine carboxamide by an adaptation of the literature
procedure (Plisson et al. 2009). The precursor (0.5 mg)
was dissolved in 0.2 mL of DMSO, and the mixture vor-
texed to dissolve it and 4 μL of tetrabutylammonium fluo-
ride (1 M in THF with 4–7 % water). [11C]Methyl iodide,
prepared from 11CO2 using a GEMS automated system (GE
Healthcare) was passed through the solution in a stream of
helium gas. The vessel was sealed and heated at 100 °C for
5 min. HPLC solvent (1 mL CH3CN/phosphate buffer
(0.024 M, pH07.2 (27:73)) was added to the reaction ves-
sel, and the solution was transferred onto semipreparative
HPLC column (Phenomenex Gemini C18 (250×10 mm,
5 μm) and flow 4.5 mL/min). The precursor elutes at
∼14 min and the [11C]GSK189254 elutes at ∼19 min. The
HPLC solvent is removed from the product fraction by
rotary evaporation, and the product is dissolved in 5 mL
saline and filtered through a 0.22-μm filter. Rapid TLC of
the product cospotted with an authentic standard is run on
Analtech UNIPLATE with methanol/ethyl acetate (1:1)
(Rf055).
Baboon preparation
Baboon studies were approved by the Brookhaven Institu-
tional Animal Care and Use Committee. Adult female
baboons (Papio anubis) (average weight 16.9 kg) were
anesthetized with an intramuscular injection of ketamine
hydrochloride (10 mg/kg), intubated, and for studies in
which drug is administered orally, a nasogastric tube was
installed. The baboon was transported to the PET laboratory
and maintained on a gaseous mixture of oxygen, nitrous
oxide, and isoflurane throughout the imaging session. Cath-
eters were placed in an antecubital vein for radiotracer
injection and for plasma sampling for drug quantification
and in the radial artery for blood sampling for radiotracer
quantification. EKG, blood pressure, O2 saturation, and
respiratory settings were continuously monitored through-
out the study.
PET scans
For brain imaging, the head of the baboon was positioned at
the center of the field of view as defined by imbedded laser
lines. Scanning was performed on a high-resolution PET
scanner (Siemens HR+, 63 slices, 4.5×4.5×4.8 mm) in 3D
mode. A transmission scan is obtained with a 68Ge rotating
source for attenuation correction of the emission data. For
each PET study 1.01–4.8 mCi of [11C]GSK189254 was
injected intravenously. The specific activity of the [11C]
GSK189254 averaged 1.62±1.83 Ci/μmol (range 0.15–
5.04 Ci/μmol at time of radiotracer administration, 66 min
post end of cyclotron bombardment) for the baseline scans.
The mass injected averaged 2.84±3.4 μg (range 0.073–
13.0 μg). Emission data were collected in 3D mode for
90 min using a 35-frame acquisition sequence (1×10, 12×
5, 1×20, 1×30, 8×60, 4×300, and 8×450 s frames). Arte-
rial plasma samples were obtained throughout the time
course of the study (every 2.5 s for the first 2 min (count
every other one) and then at 5, 10, 20, 30, 60, and 90 min).
Samples at 5, 10, 30, 60, and 90 min were analyzed for
unchanged [11C]GSK189254.
Plasma C-11 analysis
Arterial whole blood samples from either an automated
blood sampling device (first 2 min) or hand-drawn samples
were centrifuged for 1.5 min at 13,200 rpm in heparinized
Eppendorf tubes. Plasma was aliquoted (typically 0.1–
0.4 mL) by pipette from the spun samples, and radioactivity
is assayed using a calibrated NaI well-type gamma counter.
Plasma from six arterial whole blood samples (1, 5, 10, 30,
60, and 90 min after injection) is separated (as above),
aliquoted (0.1–0.6 mL), and diluted with 3 mL of water.
The diluted samples were then processed automatically by a
commercially available laboratory robot (Zymark, Caliper
Life Sciences) in the following manner. The diluted plasma
was poured onto a preconditioned (5 mL methanol followed
by 5 mL pH 7 phosphate buffer) solid-phase extraction
cartridge (C18, 500 mg, Bond Elut LRC, Varian) preloaded
with 2 mL of water and pushed into a clean test tube. The
cartridge was then rinsed sequentially with 5 mL and 2×
5 mL 60 % methanol/water, collecting each rinse fraction in
a separate clean test tube. The radioactivity of all the rinse
fractions, the total radioactivity in the sample tube, the C18
cartridge, and the empty sample tube was then assayed in a
NaI well-type gamma counter. Data were corrected as de-
scribed above, and the percentage of parent compound
remaining at each sampling time was computed from the
ratio of the C18 cartridge radioactivity to the sum of the
radioactivity from all the rinse fractions and the cartridge.
The fraction of total C-11 in the chemical form of [11C]
GSK189254 at selected time points is used to correct the
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time–activity curve of total C-11 to generate the arterial
input function which is used for the estimation of the total
distribution volume VT of each brain region.
Image and data analysis
Time frames for the PETscans were summed from 0 to 90min
for the purpose of region of interest (ROI) placement. Regions
of interest were placed over the striatum, cerebellum, frontal
cortex, thalamus, cingulate, and temporal cortex, and a global
region obtained by placing an ellipse over five central planes.
ROIs are then projected back onto the dynamic frames to form
the time–activity curves for each region.
Regional total distribution volumes (VT) were estimated
using graphical analysis (Logan et al. 1990). In order to
determine the possible effect of tracer mass on VT estimates,
the global total distribution volume (VT) vs the micrograms
per kilogram (mg/kg) of injected tracer from 13 baseline
studies was fit to the function as follows:
VT ¼ VND þ VS= 1þ x=ED50ð Þ ð1Þ
using SigmaPlot (x is in mg/kg; the fitting parameters are VS,
the specific binding component; VND, the non-displaceable
(nonspecific) component of the distribution volume; and
ED50, the dose that occupies 50 % of the receptors). Vs is
proportional to the number of free receptors (Bmax if there is no
binding due to endogenous ligand). In the absence of a mass
effect, VT0VND+VS. The corresponding occupancy (Occ) due
to unlabelled tracer mass is given as:
Occ ¼ x= ED50 þ xð Þ ð2Þ
Using the values for VND and ED50, the true VS can be
determined from the measured mg/kg. This was done for all
regions from the baseline studies. In the case of test/retest,
the baseline study was corrected (using Eq. (1)), and the
effective occupancy (Occ) of the second (retest) study was
estimated using Eq. (3), known as a Lassen plot (Cunningham
et al. 2010):
VBaseT  VRetestT ¼ Occ VBaseT  VND
  ð3Þ
where Occ is the sum of the occupancy due to mass of the
second injection as well as the carryover mass from the first
study. Using this occupancy, VTs from the retest study can be
corrected and compared to the first study. For pretreatment
studies with JNJ39220675, the occupancy for each blocking
study was also estimated using a Lassen plot with the VT
baseline VBaseT corrected for injected tracer mass (where
necessary with Eq. (1)):
VBaseT  VDrugT ¼ Occ VBaseT  VND
  ð4Þ
However this occupancy has three components: occu-
pancy due to drug, to mass from the second injection,
and to carryover mass from the first injection. Except
for the case in which the tracer mass in both injections
is very low, the actual drug occupancy will be an
approximation.
The percentage change in VT was calculated as




T was corrected for
tracer mass.
JNJ-39220675 analysis
Plasma concentrations of JNJ-39220675 were deter-
mined using liquid chromatography/tandem mass spec-
trometry (LC-MS/MS) analysis. A 1 mg/mL stock
solution of JNJ-39220675 was prepared in dimethyl
sulfoxide and further diluted in acetonitrile (1:20, v/v)
to yield a 50-μg/mL working solution. Five microliters
of the working solution was spiked into 995 μL of
blank baboon plasma to yield 250 ng/mL concentration
of JNJ-39220675 in plasma, which was then serially
diluted to 125, 25, 5, 1, and 0.2 ng/mL with blank
baboon plasma. A 2-mL 96-well plate was used for
sample preparation. A 50-μL aliquot of each standard
and incurred plasma sample was mixed with 150 μL of
acetonitrile containing JNJ-40579513 (50 ng/mL) as in-
ternal standard and was vortexed for 1 min to precipi-
tate the plasma proteins. The quality control (QC)
samples (2, 40, and 200 ng/mL) were prepared from
the 50 μg/mL working solution in the same manner as
above. The plate with the standards, QC samples, un-
known samples, and plasma blanks was then centrifuged
for 5 min at 6,100× g. The supernatant was diluted 1:1
with water before injection onto the LC-MS/MS system.
The LC-MS/MS system comprised of an API 4000
tandem mass spectrometry (Applied Biosystems, Foster
City, CA), two LC-20AD pumps with a CBM-20AD
controller (Shimadzu, Columbia, MD), a LEAP CTC
HTS PAL autosampler (CTC Analytics, Carrboro, NC),
and a switching valve (Valco, Huston, TX The chroma-
tography) was performed on a Phenomenex Synergi,
hydro-RP column (2×50 mm, 4 μm particle size) using
a gradient elution method (0–95 % B over 1.0 min) at a
flow rate of 0.7 mL/min. The mobile phase consisted of
10 mM ammonium acetate in water (A) and 0.1 %
formic acid in acetonitrile/methanol (1:1, v/v) mixture
(B). The samples were analyzed in the Multiple Reac-
tion Monitoring scan mode with electrospray ionization.
JNJ 39220675 was monitored for the following transi-
tion: 370.1→216.0. The data were processed using An-
alyst software (Applied Biosystems, Foster City, CA).
The lower limit of quantification was 0.2 ng/mL.
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Results
Baseline scans
The highest uptake of C-11 after [11C]GSK189254 admin-
istration occurred in the striatum with lower levels in frontal
and temporal cortex consistent with results of Martinez-Mir
et al. (1990). The lowest uptake occurred in the cerebellum.
Low specific activity [11C]GSK189254 resulted in lower
overall brain uptake with peak uptake occurring earlier and
brain regions clearing over time. In contrast, with higher
specific activity (and lower mass), C-11 steadily accumu-
lates over the 90-min scanning period.
A plot of the global VT vs injected dose in mg/kg for 13
baseline studies is shown in Fig. 2a. The solid line is the fit
using Eq. (1) where ED5000.16 μg/kg, VND02.8, and VS0
49 mL/cm3. The predicted occupancy is shown in Fig. 2b.
From this plot, [11C]GSK189254 binding is highly sensitive
to injected mass even at doses less than 0.1 μg/kg. Accord-
ing to this data, a fractional occupancy of <0.1 would
require the administration of <0.02 μg/kg.
Average baseline VTs for striatum (Str), cingulate gyrus
(Cng), temporal (Tmp), frontal (Fr), thalamus (Thl), and
cerebellum (Cb) are shown in Fig. 3, both corrected and
uncorrected for mass effects. The ratio of VS for Str to Cb is
∼3.1 (using the corrected VTs and assuming VND is on the
order of three) so that the Bmax in Str is approximately three
times that in Cb.
A test/retest study on the same day in which the baseline
and retest scans had injected masses of 0.78 and 0.33 μg/kg,
respectively, had the same global VT, 10.7 vs 10.4 mL/cm
3.
This indicates a significant carryover mass in the second
study since the predicted Occ’s for baseline and retest were
0.83 and 0.67, respectively, based on Eq. (1) which should
have resulted in different VTs. This was verified using a
Lassen plot (Cunningham et al. 2010). Correcting the base-
line VTs for a mass of 0.78 μg/kg and using the retest VTs in
Eq. (3) gives Occ00.87 for the retest study with 0.2 for the
carryover occupancy. The average percentage change over
six ROIs was −8.9±4.9 % after correction compared to 7±
4.3 % before correction. The global and striatal VTs were
49.7 (test) and 50.0 mL/cm3 (retest), and 109 (test) and
113 mL/cm3(retest), respectively. The Lassen plot also pro-
vides an estimate ofVND, and this was found to be 4.4 mL/cm
3
which is slightly higher than 2.8 mL/cm3 for the baboon group
as a whole using Eq. (1). Repeating the calculation using
VND04.4 mL/cm
3 to correct the baseline scan gave the same
occupancy for the second study. In another test/retest study
(Lulu), 1 month apart with injected masses of 0.0065 and
0.022 μg/kg, the global and striatal VTs (corrected for mass
as described above) were 47.5 (test) and 51.4 (retest) for
global, and 118.5 (test) and 124 (retest) for striatal. The
average percentage change over six regions was 2.8±8.8 %.
The test/retest, 2 years apart (Kennedy), had global VTs of 45
and 65 for the earlier and later scans (corrected for mass) and
an average difference of −37±0.5 %.
Treatment with JNJ-39220675
The intravenous administration of JNJ-39220675 (1 mg/kg)
in three different animals markedly reduced uptake of [11C]
GSK189254 in all brain regions relative to a baseline scan
consistent with robust blockade of baboon brain histamine
H3 receptors. In these three studies, the injected masses of
GSK189254 at baseline were 0.31, 0.74, and 0.006 μg/kg
and 0.084, 0.18, and 0.007 μg/kg for the corresponding drug
intervention scan. In the first two cases, the baseline scan
must be corrected for mass, and the occupancy calculated



















Fig. 2 Effect of radiotracer mass of GSK189254 on distribution volume (VT) (a) global distribution volume vs μg/kg of tracer mass. The solid line
is the fit to the model shown and (b) predicted histamine H3 occupancy based on the model of Eq. (2)
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for the drug study will contain a contribution from tracer
mass. For the first two studies, the calculated fractional
occupancies in the second scan were 0.97 and 0.94 with
VNDs of 3.4 and 4.5 mL/cm
3. However a substantial fraction
of these occupancies is due to tracer mass in the second
study. Uptake TACs and VTs for baseline and blocked high-
specific activity study (0.006 μg/kg) are shown in Fig. 4a, b,
respectively. The average decrease in VT from baseline
across brain regions was 87.8±2.8 % (paired t07.2,
p00.002). A Lassen plot for this study is shown in
Fig. 4c. In this case, the fractional occupancy of 0.96 would
be expected to be almost totally due to JNJ-39220675.
JNJ 39220675 administered via a nasogastric tube also
produced a robust reduction of [11C]GSK189254 uptake and
of the corresponding VT in all brain regions in two animals
scanned at 1.5 and 4 h post-administration. In these two
studies, the injected masses of GSK189254 associated with
the [11C]GSK189254 at baseline were 0.147 and 0.015 μg/kg.
For the second study (0.015 μg/kg), the fractional occupancy
was calculated to be 0.88 and 0.94 at 1.5 and 4 h for which the
injected tracer masses were 0.005 and 0.003 μg/kg, respec-
tively. The carryover mass should be low for these, so the
occupancies reflect that of JNJ 39220675. Also the percentage
reduction in VT at 4 h was significantly greater than that at
1.5 h (t04.1, p<0.01). Figure 5 shows PET images, TACs,
and VTs for the three scans. For the other study the fractional
occupancies were 0.98 at 1.5 and 4 h but the injected tracer
masses were 0.78 and 0.43 μg/kg, respectively, so the occu-
pancies most likely reflect both tracer and JNJ 39220675.
From the blocking studies and the test/retest study, the
average non-displaceable component of the total distribution
volume, VND from Lassen plots was found to be 4.78±
1.02 mL/cm3 which is somewhat higher than predicted by the
model of Eq. (1). Using an exponential fit instead of Eq. (1)
VT0VND+VS exp(−x/ED50) predicts VND08.1, VS041mL/cm3
(global), and ED5000.14 μg/kg. The ED50s for both functions
are close, but the exponential function appears to overestimate
VND, while Eq. (1) underestimates it. The average obtained
from the baseline Lassen plots is in between at 4.7 mL/cm3.
In all cases, use of a higher VND did not change the occupancy
calculated using the Lassen plot. From these studies, we esti-
mate that a 1-mg/kg dose of JNJ 39220675 administered either
intravenously or orally blocks ∼90 % of [11C]GSK189254
specific binding in the anesthetized female baboon.
Discussion
PET imaging with highly specific radiotracers is a safe, rela-
tively noninvasive method to determine whether a drug enters
the brain and engages a specific molecular target in humans and
in animals in vivo (Nutt et al. 2007). PET has been applied to
the development of new drugs (Fowler et al. 2010) as well as to
the investigation of the pharmacokinetic and pharmacodynam-
ic effects of approved drugs (Volkow et al. 2009). When the
radiotracer is labeled with carbon-11, serial studies can be
performed in the same individual (baseline PET scan and up
to three more PET scans in a day), allowing an individual to
serve as his/her own control and reducing the effect of inter-
subject and intrasubject variability (Volkow et al. 2005). When
plasma drug levels are also measured, the relationship between
drug PK and drug occupancy can be assessed, and when such a
relationship is found, plasma drug levels can be used as a
surrogate for drug occupancy in the brain (Fowler et al. 2010).
The main finding from this study is that the aryloxypyr-
idine amide, JNJ-39220675, administered either intrave-
nously or orally at a dose of 1 mg/kg enters the brain and
produces robust blockade of brain histamine H3 receptors as
determined by reduction of [11C]GSK189254 binding rela-
tive to a baseline scan and occupancy calculations. In this same
study, we report the high sensitivity of [11C]GSK189254 bind-
ing to mass and carryover effects corroborating a recent report
in humans (Ashworth et al. 2010). An in vitro comparison of
GSK189254 (used as the tracer in this study) with JNJ-
39220675 (used as the drug) indicates both to be potent func-
tional antagonists at the human H3 receptor. For both com-
pounds, Ki (pA2) values were found to be 0.12 nM (9.4) and
1.4 nM (10.4) for GSK189254 and JNJ-39220675, respectively
(details of the assays are provided in Letavic et al. (2008) and
Barbier et al. (2004)). Since JNJ-39220675 has not yet been
labeled, details of the in vivo kinetics cannot be compared to
GSK189254.
JNJ-39220675 inhibited >90 % of the binding of [11C]
GSK189254 after i.v. or oral administration of a dose of
1 mg/kg. This is consistent with good blood–brain barrier
penetration predicted by JNJ-39220675's physical properties
(MW 369.44, log D 2.08) (Letavic et al. 2010). It is also
consistent with its preclinical profile reporting that JNJ-













VT  corrected for tracer mass
VT uncorrected
Fig. 3 Average baseline VTs (n013) for striatum (Str), cingulate gyrus
(Cng), temporal (Tmp), frontal (Fr), thalamus (Thl), and cerebellum
(Cb) uncorrected and corrected for mass effects
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histamine H3 receptor and that it occupies 90 % of histamine
H3 receptors at a dose of 1 mg/kg in rats, mice, and dogs
following oral administration (Letavic et al. 2010).
In the current study, a separate bioanalysis of the con-
centration of JNJ-39220675 at two time points after oral
administration showed that the 90 % receptor occupancy
corresponded to plasma concentrations of 1 and 1.3 ng/cc at
the beginning and end of the second scan. We note that
histamine H3 occupancy levels of 90 % effectively reduced
alcohol intake and preference in a genetic model of human
alcoholism, while an occupancy level of 75 % was not
effective. This highlights the importance of accurate esti-
mates of receptor occupancy vs dose in human clinical trials
prior to interpreting clinical results.
For JNJ-39220675, we have previously demonstrated the
relationship between receptor occupancy and histamine re-
lease in the frontal cortex of freely moving rats (Letavic et
al. 2010). We observed that high receptor occupancy (ap-
proximately 90 %) was required for a statistically significant
increase in histamine levels and that this correlated with
EEG measurements showing a statistically significant in-
































Fig. 4 Time–activity curves and VT for [
11C]GSK189254 for one of
the baboons for (a) the striatum, the cerebellum, and the global region
at baseline and 10 min after i.v. administration of JNJ-39220675;
injected mass of GSK189254 at baseline was 0.006 μg/kg. Note that
after JNJ-39220675, time–activity curves for the different brain regions
are indistinguishable. (b) Corresponding VTs at baseline and 10 min
after JNJ-39220675 showing a significant reduction after drug (paired t
test, p00.002). (c) Lassen plot for estimation of occupancy (0.97) and
VND (4.6 mL/cm
3). Data points are for the different regions of interest
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for effects on cognition (unpublished). The correlation be-
tween receptor occupancy and wakefulness has also been
reported for other histamine H3 receptor antagonists
(Raddatz et al. 2012), and wake-promoting activity is only
observed at doses producing greater than 80 % receptor occu-
pancy (Letavic et al. 2010). Consequently, recognizing that
the effect of a histamine H3 antagonist on alcohol intake and
preference is due to changes in brain histamine concentration,
and the relationship between histamine levels and histamine
H3 receptor occupancy noted above, one would anticipate a
requirement for high receptor occupancy for efficacy.
While the injected mass for a radiotracer for serial studies
in the same individual in the same day are usually not
subject to mass and carryover effects, the use of high-
affinity radiotracers like [11C]GSK189254 (0.1 nM;(Plisson
et al. 2009)) requires a special caution. Even at relatively low
injected mass (<0.1 μg/kg of GSK189254), we saw a signif-
icant mass effect on baseline scans (Fig. 4) and dramatic
reduction in VT at doses >0.1 μg/kg. In fact, a prior study in
humans reported that in order to occupy <5% of histamine H3
receptors, no more than 0.003 μg/kg should be administered.
Low injected mass (<1 μg/kg) could be achieved by long
cyclotron irradiation and by limiting the amount of [11C]
GSK189254 injected to 1 mCi in the baboon.
We note that even at the high dose of JNJ-39220675 admin-
istered in these studies, residual binding of [11C]GSK189254
remained. This non-displaceable binding (VND) averaged
4.78±1.02 mL of plasma/cm3 of tissue for the six brain regions
and was accounted for in the estimation of receptor occupancy.
For comparison, the VND of 10.54±1.78 mL of plasma/cm
3 of
tissue has been reported for human dose–receptor occupancy
studies with [11C]GSK189254 (Ashworth et al. 2010).
In summary, a growing number of structurally diverse
chemical compounds with high specificity and high affinity
for the histamine H3 receptor have been reported. The cur-
rent PET study establishes mass requirements to minimize
mass and carryover effects from [11C]GSK189254 for the
anesthetized baboon, and this baseline data should be appli-
cable to PET studies of other histamine H3 receptor active
chemical compounds. It also extends the prior preclinical
study of JNJ-39220675 (Letavic et al. 2010) and demon-
strates good blood–brain barrier penetration and robust
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Fig. 5 Effect of oral
administration of JNJ 39220675
(1 mg/kg) on (a) PET images at
the level of the striatum, (b)
time–activity curves, and (c)
corresponding VTs (baseline
corrected for mass) for JNJ
39220675 administered via a
nasogastric tube. A robust
reduction of [11C]GSK189254
uptake is observed at 90 min
and further reduction at
242 min (global VTs 57, 11.4,
and 8 mL/cm3 for baseline for
90 and 242 min)
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histamine H3 receptor blockade after i.v. and oral adminis-
tration of a dose of 1 mg/kg.
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